Literature DB >> 21904809

Bile culture and susceptibility testing of malignant biliary obstruction via PTBD.

Haipeng Yu1, Zhi Guo, Wenge Xing, Xiuying Guo, Fang Liu, Baoguo Li.   

Abstract

PURPOSE: To assess the information obtained by bile culture and susceptibility testing for malignant biliary obstruction by a retrospective one-center study.
METHODS: A total of 694 patients with malignant biliary obstruction received percutaneous transhepatic biliary drainage during the period July 2003 to September 2010, and subsequently, bile specimens were collected during the procedure. Among the 694 patients, 485 were men and 209 were women, ranging in age from 38 to 78 years (mean age 62 years).
RESULTS: A total of 42.9% patients had a positive bile culture (298 of 694). Further, 57 species of microorganisms and 342 strains were identified; gram-positive bacteria accounted for 50.9% (174 of 342) and gram-negative bacteria accounted for 41.5% (142 of 342) of these strains. No anaerobes were obtained by culture during this study. The most common microorganisms were Enterococcus faecalis (41 of 342, 11.9%), Escherichia coli (34 of 342, 9.9%), Klebsiella pneumoniae (28 of 342, 8.2%), Staphylococcus epidermidis (19 of 342, 5.5%), Enterococcus (18 of 342, 5.3%), and Enterobacter cloacae (16 of 342, 4.7%). The percentage of β-lactamase-producing gram-positive bacteria was 27.6% (48 of 174), and the percentage of gram-negative bacteria was 19.7% (28 of 142). The percentage of enzyme-producing Escherichia coli was 61.7% (21 of 34).
CONCLUSION: The bile cultures in malignant biliary obstruction are different from those in the Tokyo Guidelines and other benign biliary obstruction researches, which indicates that a different antibacterial therapy should be applied. Thus, knowledge of the antimicrobial susceptibility data could aid in the better use of antibiotics for the empirical therapy of biliary infection combined with malignant biliary obstruction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21904809     DOI: 10.1007/s00270-011-0263-2

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  7 in total

1.  Differences in bile microbiology according to region and hospital: response to correspondence on "Bile microbiology at a hospital in southern Taiwan".

Authors:  W Kwon; S-W Kim; J-Y Jang
Journal:  Infection       Date:  2013-02-10       Impact factor: 3.553

2.  Malignant biliary obstructions: can we predict immediate postprocedural cholangitis after percutaneous biliary drainage?

Authors:  Shin Ahn; Yoon-Seon Lee; Kyung Soo Lim; Jae-Lyun Lee
Journal:  Support Care Cancer       Date:  2013-03-26       Impact factor: 3.603

3.  Changing trend in bile microbiology and antibiotic susceptibilities: over 12 years of experience.

Authors:  W Kwon; J-Y Jang; E-C Kim; J W Park; I W Han; M J Kang; S-W Kim
Journal:  Infection       Date:  2012-11-21       Impact factor: 3.553

4.  Clinical epidemiology and outcomes of biliary tract infections caused by Klebsiella pneumoniae.

Authors:  Lanyu Li; Changqing Zhu; Huan Huang
Journal:  Ann Transl Med       Date:  2019-07

5.  Microbial Profiles and Risk Factors of Preexisting Biliary Infection in Patients with Therapeutic Endoscopy.

Authors:  Hua-Qiang Ruan; Guo-Lin Liao; Peng Peng; Shi-Quan Liu; Chang-Liang Wu; Jian-Fu Qin; Zhi-Hai Liang; Guo-Du Tang; Meng-Bin Qin; Jie-An Huang
Journal:  Gastroenterol Res Pract       Date:  2019-05-05       Impact factor: 2.260

6.  Biliary Microbial Structure of Gallstone Patients With a History of Endoscopic Sphincterotomy Surgery.

Authors:  Hongzhang Shen; Juanjuan Zhu; Fuqiang Ye; Dongchao Xu; Liangliang Fang; Jianfeng Yang; Huijie Lv; Qifeng Lou; Hangbin Jin; Ming Ni; Xiaofeng Zhang
Journal:  Front Cell Infect Microbiol       Date:  2021-01-27       Impact factor: 5.293

7.  Intractable Biliary Candidiasis in Patients with Obstructive Jaundice and Regional Malignancy: A Retrospective Case Series.

Authors:  Abdel Rahman A Al Manasra; Khaled Jadallah; Abdelwahab Aleshawi; Mamoon Al-Omari; Mwaffaq Elheis; Ahmad Reyad; Jehad Fataftah; Hamzeh Al-Domaidat
Journal:  Clin Exp Gastroenterol       Date:  2021-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.